Hepatitis Monthly

Published by: Kowsar

Influencing Factors on the Outcome and Prognosis of Patients With HBV Infction: Seven Years Follow-up

Shahnaz Sali 1 , * , Seyed Moayed Alavian 2 , Graham R Foster 3 , Hossein Keyvani 4 , Leila Mehrnoosh 2 and Navid Mohammadi 5
Authors Information
1 Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
2 Baqiyatallah Research Center for Gastroenterology and Liver Disease, Tehran, IR Iran
3 Queen Mary, University of London, the Liver Unit, London, UK
4 Department of Virology, Tehran University of Medical Science, Tehran, IR Iran
5 Department of Community Medicine, Faculty of medicine, Tehran University of Medical Sciences, Tehran, IR Iran
Article information
  • Hepatitis Monthly: July 01, 2013, 13 (7); e8743
  • Published Online: July 8, 2013
  • Article Type: Research Article
  • Received: October 23, 2012
  • Revised: May 12, 2013
  • Accepted: June 8, 2013
  • DOI: 10.5812/hepatmon.8743

To Cite: Sali S, Alavian S M, Foster G R, Keyvani H, Mehrnoosh L, et al. Influencing Factors on the Outcome and Prognosis of Patients With HBV Infction: Seven Years Follow-up, Hepat Mon. 2013 ; 13(7):e8743. doi: 10.5812/hepatmon.8743.

Copyright © 2013, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1.
  • 2. Ashraf H, Alam NH, Rothermundt C, Brooks A, Bardhan P, Hossain L, et al. Prevalence and risk factors of hepatitis B and C virus infections in an impoverished urban community in Dhaka, Bangladesh. BMC Infect Dis. 2010; 10: 208[DOI][PubMed]
  • 3. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004; 11(2): 97-107[PubMed]
  • 4. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007; 45(2): 507-39[DOI][PubMed]
  • 5. Kao JH, Chen DS. Global control of hepatitis B virus infection. Lancet Infect Dis. 2002; 2(7): 395-403[PubMed]
  • 6. Zaki H, Darmstadt GL, Baten A, Ahsan CR, Saha SK. Seroepidemiology of hepatitis B and delta virus infections in Bangladesh. J Trop Pediatr. 2003; 49(6): 371-4[PubMed]
  • 7. Kidd-Ljunggren K, Myhre E, Blackberg J. Clinical and serological variation between patients infected with different Hepatitis B virus genotypes. J Clin Microbiol. 2004; 42(12): 5837-41[DOI][PubMed]
  • 8. Chen CH, Lee CM, Hung CH, Hu TH, Wang JH, Wang JC, et al. Clinical significance and evolution of core promoter and precore mutations in HBeAg-positive patients with HBV genotype B and C: a longitudinal study. Liver Int. 2007; 27(6): 806-15[DOI][PubMed]
  • 9. Tacke F, Manns MP, Trautwein C. Influence of mutations in the hepatitis B virus genome on virus replication and drug resistance--implications for novel antiviral strategies. Curr Med Chem. 2004; 11(20): 2667-77[PubMed]
  • 10. Alavian SM, Hajarizadeh B, Ahmadzad-Asl M, Kabir A, Bagheri-Lankarani K. Hepatitis B Virus Infection in Iran: A Systematic Review. Hepat Mon. 2008; 8(4): 281-294
  • 11. Yuen MF, Yuan HJ, Wong DK, Yuen JC, Wong WM, Chan AO, et al. Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. Gut. 2005; 54(11): 1610-4[DOI][PubMed]
  • 12. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol. 2009; 50(2): 227-42[DOI][PubMed]
  • 13. Liaw YF, Tai DI, Chu CM, Chen TJ. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology. 1988; 8(3): 493-6[PubMed]
  • 14. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009; 50(3): 661-2[DOI][PubMed]
  • 15. Yim HJ, Lok AS. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology. 2006; 43(2 Suppl 1)-81[DOI][PubMed]
  • 16. Chavez S.
  • 17. Farhat A, Khademi G, Mazlouman SJ. The prevalence of hepatitis B carrier state in Khorassan province of Iran. Saudi Med J. 2003; 24(5): 549-51[PubMed]
  • 18. Merat S, Malekzadeh R, Rezvan H, Khatibian M. Hepatitis B in Iran. Arch Iranian Med. 2000; 3(4): 192-201
  • 19. Moucari R, Korevaar A, Lada O, Martinot-Peignoux M, Boyer N, Mackiewicz V, et al. High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study. J Hepatol. 2009; 50(6): 1084-92[DOI][PubMed]
  • 20. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006; 130(3): 678-86[DOI][PubMed]
  • 21. Yu MW, Hsu FC, Sheen IS, Chu CM, Lin DY, Chen CJ, et al. Prospective study of hepatocellular carcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers. Am J Epidemiol. 1997; 145(11): 1039-47[PubMed]
  • 22. Hsu YS, Chien RN, Yeh CT, Sheen IS, Chiou HY, Chu CM, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology. 2002; 35(6): 1522-7[DOI][PubMed]
  • 23. Chu CM, Hung SJ, Lin J, Tai DI, Liaw YF. Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels. Am J Med. 2004; 116(12): 829-34[DOI][PubMed]
  • 24. Huo T, Wu JC, Hwang SJ, Lai CR, Lee PC, Tsay SH, et al. Factors predictive of liver cirrhosis in patients with chronic hepatitis B: a multivariate analysis in a longitudinal study. Eur J Gastroenterol Hepatol. 2000; 12(6): 687-93[PubMed]
  • 25. Lin SM, Yu ML, Lee CM, Chien RN, Sheen IS, Chu CM, et al. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol. 2007; 46(1): 45-52[DOI][PubMed]
  • 26. Manno M, Camma C, Schepis F, Bassi F, Gelmini R, Giannini F, et al. Natural history of chronic HBV carriers in northern Italy: morbidity and mortality after 30 years. Gastroenterology. 2004; 127(3): 756-63[PubMed]
  • 27. Mazzella G, Saracco G, Festi D, Rosina F, Marchetto S, Jaboli F, et al. Long-term results with interferon therapy in chronic type B hepatitis: a prospective randomized trial. Am J Gastroenterol. 1999; 94(8): 2246-50[DOI][PubMed]
  • 28. Moreno-Otero R, Garcia-Monzon C, Garcia-Sanchez A, Garcia Buey L, Pajares JM, Di Bisceglie AM. Development of cirrhosis after chronic type B hepatitis: a clinicopathologic and follow-up study of 46 HBeAg-positive asymptomatic patients. Am J Gastroenterol. 1991; 86(5): 560-4[PubMed]
  • 29. Brunetto MR, Oliveri F, Rocca G, Criscuolo D, Chiaberge E, Capalbo M, et al. Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen. Hepatology. 1989; 10(2): 198-202[PubMed]
  • 30. Fattovich G, Brollo L, Alberti A, Pontisso P, Giustina G, Realdi G. Long-term follow-up of anti-HBe-positive chronic active hepatitis B. Hepatology. 1988; 8(6): 1651-4[PubMed]
  • 31. de Franchis R, Meucci G, Vecchi M, Tatarella M, Colombo M, Del Ninno E, et al. The natural history of asymptomatic hepatitis B surface antigen carriers. Ann Intern Med. 1993; 118(3): 191-4[PubMed]
  • 32. Beasley RP. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer. 1988; 61(10): 1942-56[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments